Security Name: 10.00% Dishman Carbogen Amcis Limited 26 Mar 2027
ISIN: INE385W07042
Taxable
Tax Category
26 Mar, 2026
Call Date
(6 Mo 19 D to call)
Quarterly
Interest Payment Frequency
Yes
NRI Eligibility
26 Mar, 2025
Allotment Date
NA
Put Date
26 Sep, 2025
Next Interest Payment Date
15 days
Shut Period
Both
Active on NSDL/CDSL
Non-Guaranteed
Type of Guarantee
No
Perpetual
Private Placement
Mode of Issue
Listed
Listing Details
Non Public Sector Undertaking
Type of Issuer
Quote Not Available
Dirty Price
10%
Coupon
Fixed Interest
Coupon Basis
Quote Not Available
Current Yield
11 Sep, 2025
Record Date
YOUR EARNING
Your Investment
Final Payout
₹0
Error Generating Cashflow 😥. We are looking into this.
*All Interest Payments will be subject to TDS (Not Applicable on Government Securities and Tax Free Bonds)
YOUR RISK
Repayment Priority
Higher the level, higher the priority of investment repayment on default
Security with Collateral?
An investment secured with collateral helps
ISSUER
Dishman Carbogen Amcis Limited
Incorporated in 1983, DCAL is an integrated CRAMS player. The company operates 25 multipurpose facilities across India, Switzerland, France, the Netherlands, the UK and China, and a dedicated production facility for APIs and intermediates each in Bavla and Naroda (Gujarat). DCAL’s multi-purpose manufacturing facilities at 10 sites have been approved by global health authorities, some of which are United States Food and Drug Administration, Swissmedic and Pharmaceuticals and Medical Devices Agency.
The ratio in FY24 is 7.84x and it was 10.18x in FY23, indicating decrease in debt level due to decrease in the borrowings of the issuer.
Debt/EBITDA
The ratio in FY24 is -0.51x and it was -0.66x in FY23 indicating slight increase in debt servicing ability, due to decrease in borrowings FY24.
Interest coverage ratio
Recent News
CARBOGEN AMCIS announces successful ANVISA audit of its facility in China
Sep 10, 2024 | Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited Reports Earnings Results for the Second Quarter and Six Months Ended
Nov 13, 2024 | Dishman Carbogen Amcis Limited
Dishman Carbogen subsidiary successfully completes Swissmedic inspection of its Vionnaz facility
Jan 10, 2025 | Dishman Carbogen Amcis Limited
Related Videos
What are Bonds?
From Basics to Brilliance: Unravelling the Concept of Bonds
Price & Yields
The intricate relationship between bond prices and yields
STEPS TO BUY THIS BOND
Information required for KYC
PAN Card
Bank Account Proof
Aadhaar Card
Demat Account Proof
How to exit the investment?
To know more about the Bond and the issuer, download the Information Memorandum.
To read about the reasons for the ratings assigned to the Bond, download the Rating Rationale.
Clean Price
Yield (YTC)
Principal Amount
Accrued Interest from
Select the number of units below
BOND VALUE DETAILS
Face Value
Market Value
Stamp Duty
Select a Settlement Date:
Total Investment
| Cashflow for INE385W07042 |
|---|
| Disclaimer: The actual dates and interest amounts can vary depending on Bank closures, holidays etc. Tax Deducted at Source (TDS) is applicable on interest receivable based on relevant tax regulations. You can avail TDS credit while filing your Income Tax Return (ITR). |
|---|
| Security Name |
|---|
| 10.00% Dishman Carbogen Amcis Limited 26 Mar 2027 |
| Credit Rating |
|---|
| A+ /Stable by IND |
| Coupon Frequency |
|---|
| Quarterly |
| Face Value |
|---|
| ₹1,00,000 |
| Coupon |
|---|
| 10.000000% |
| YTM or YTC |
|---|
| YTC |
| Call Date |
|---|
| 26/03/2026 |
| Security |
|---|
| Senior Secured |
| No. of Bonds |
|---|
| 1 |
| Settlement Date |
|---|
| Principal Amount |
|---|
| ₹NaN |
| Accrued Interest |
|---|
| ₹0 |
| Stamp Duty |
|---|
| ₹0 |
| Total Amount Payable |
|---|
| ₹NaN |
| Price |
|---|
| ₹NaN |
| Yield |
|---|
| % |
| Year | Payment Date | Amount | Amount after TDS | Payout Type |
|---|
Quote Not Available for purchase
Disclaimer: Investments in Debt Securities/ Municipal Debt Securities/ Securitised Debt Instruments are subject to risks including delay and/ or default in payment. Read all the Offer Related documents carefully.
Source: Issuer website, Rating Rationale, Issuer Annual Report, Information Memorandum and News from Google.
